COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries
暂无分享,去创建一个
M. Suchard | N. Shah | J. Jonnagaddala | G. Hripcsak | P. Ryan | C. Reich | M. Matheny | S. Duvall | A. Ostropolets | A. Prats-Uribe | K. Natarajan | F. Nyberg | C. Areia | P. Rijnbeek | V. Subbian | D. Morales | S. You | D. Dawoud | D. Prieto-Alhambra | K. Lynch | T. Duarte-Salles | K. Shah | M. Gong | K. Kostka | A. Golozar | J. Lane | A. Sena | T. Alshammari | H. Alghoul | P. Casajust | L. Lai | T. Falconer | Lin Zhang | M. Spotnitz | O. Alser | D. Vizcaya | C. Blacketer | E. H. Tan | J. Posada | M. Recalde | Yue Yang | E. Minty | A. Vivekanantham | S. F. Bertolin | Waheed-Ul-Rahman Ahmed | A. Abend
[1] Y. Hu,et al. [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
[2] Hyon K. Choi,et al. COVID‐19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study , 2020, Arthritis & rheumatology.
[3] M. Suchard,et al. Clinical characteristics, symptoms, management and health outcomes in 8,598 pregnant women diagnosed with COVID-19 compared to 27,510 with seasonal influenza in France, Spain and the US: a network cohort analysis , 2020, medRxiv.
[4] Rae Woong Park,et al. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study , 2020, Nature Communications.
[5] D. Micic,et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis , 2020, Annals of the Rheumatic Diseases.
[6] M. Schuemie,et al. ohdsi-studies/Covid19CharacterizationCharybdis: Charybdis v1.1.1 - Publication Package , 2020 .
[7] N. Shah,et al. Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom , 2020, medRxiv.
[8] Rahul D. Pawar,et al. Comparison Between Influenza and COVID-19 at a Tertiary Care Center , 2020, medRxiv.
[9] L. León,et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases , 2020, Annals of the Rheumatic Diseases.
[10] M. Luppi,et al. COVID-19, coagulopathy and venous thromboembolism: more questions than answers , 2020, Internal and Emergency Medicine.
[11] M. Dimopoulos,et al. Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes , 2020, Rheumatology International.
[12] K. Bhaskaran,et al. OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.
[13] Mingmin Zhang,et al. Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study , 2020, Annals of the Rheumatic Diseases.
[14] Soumitra Sengupta,et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series , 2020, BMJ.
[15] Yeong-Wook Song,et al. Care for patients with rheumatic diseases during COVID‐19 pandemic: A position statement from APLAR , 2020, International journal of rheumatic diseases.
[16] Karsten M. Borgwardt,et al. Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis , 2020, Travel Medicine and Infectious Disease.
[17] L. Trupin,et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2020, Annals of the Rheumatic Diseases.
[18] A. Neimann,et al. Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York , 2020, The New England journal of medicine.
[19] C. Morélot-Panzini,et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine , 2020, Annals of the Rheumatic Diseases.
[20] M. Agha,et al. Evidence based management guideline for the COVID-19 pandemic - Review article , 2020, International Journal of Surgery.
[21] C. Montecucco,et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies , 2020, Annals of the Rheumatic Diseases.
[22] Taojiao Wang,et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.
[23] W. Gong,et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. , 2020, JAMA cardiology.
[24] Xin Zhou,et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.
[25] Alejandro Lucia,et al. Chronic inflammation in the etiology of disease across the life span , 2019, Nature Medicine.
[26] Dong Sook Kim,et al. Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data , 2017, Journal of Korean medical science.
[27] Rae Woong Park,et al. Characterizing treatment pathways at scale using the OHDSI network , 2016, Proceedings of the National Academy of Sciences.
[28] Vivienne J. Zhu,et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases , 2015, J. Am. Medical Informatics Assoc..
[29] T. Ortel,et al. Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases , 2014, Journal of Thrombosis and Thrombolysis.
[30] M. Wasko,et al. Cardiovascular disease in autoimmune rheumatic diseases. , 2013, Autoimmunity reviews.
[31] Sreeram V Ramagopalan,et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study , 2011, BMC medicine.
[32] Peter C. Austin,et al. Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..
[33] M. Turiel,et al. Cardiovascular involvement in systemic autoimmune diseases. , 2009, Autoimmunity reviews.
[34] Yu-Chuan Li,et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers , 2015, MedInfo.
[35] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[36] J. Sundquist,et al. Autoimmune diseases and venous thromboembolism: a review of the literature. , 2012, American journal of cardiovascular disease.
[37] Daniel Prieto-Alhambra,et al. Construction and validation of a scoring system for the selection of high-quality data in a Spanish population primary care database (SIDIAP). , 2011, Informatics in primary care.